Coronary heart disease risks and lifestyle behaviors in persons with HIV infection

Journal of the Association of Nurses in AIDS Care

Volumn 17, Issue 3, 2006, Pages 3-17

  Salyer, Jeanne ^a   Lyon, Debra E ^a   Settle, Jane ^b   Elswick, R K ^a   Rackley, Dwight ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular risks factors; HIV associated lipodystrophy syndrome; Lifestyle behaviors

Indexed keywords

EID: 33745126973     PISSN: 10553290     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jana.2006.03.001     Document Type: Article

References (45)

1. Barbaro G., Di Lorenzo G., Gianaspro G., et al. (2002, July). Incidence of coronary artery disease in HIV-infected patients not on protease inhibitors: A randomized, multicenter trial (Abstract WeOrB1307). Paper presented at the XIV International AIDS Conference, Barcelona, Spain.
2. Bergersen, B. M., Sandvik, L., Bruun, J. N., & Tonstad, S. (2004). Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: Results from a Norwegian study of 721 subjects. European Journal of Clinical Microbiology and Infectious Diseases, 23, 625-630.
3. Bollens D., Guiguet M., Tangre P., Rachline R. A., Meynard J. L., Benlian P., et al. (2001, December). Family history, immuno-infectious status and type of antiretroviral drug regimen are predictors for major hypertriglyceridemia in HIV infected patients (Abstract No. I-220). Paper presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago.
4. Bozzette, S. A., Joyce, G., McCaffrey, D. F., Leibowitz, A. A., Morton, S. C., Berry, S. H., et al., and The HIV Cost and Services Utilization Study Consortium (2001). Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. New England Journal of Medicine, 344, 817-823.
5. Brunner, E., White, I., Thorogood, M., Bristow, A., Curle, D., & Marmot, M. (1997). Can dietary interventions change diet and cardiovascular risk factors? A meta-analysis of randomized controlled trials. American Journal of Public Health, 87, 1415-1422.
6. Carr, A., & Cooper, D. A. (1998). Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor. New England Journal of Medicine, 339, 1296
7. Carr, A., Emery, S., Law, M., Puls, R., Lundgren, J. D., & Powderly, W. G. (2003). An objective case definition of lipodystrophy in HIV-infected adults: A case control study. The Lancet, 361, 726-735.
8. Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D. J., et al. (1998). A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS, 12, F51-F58.
9. Carr, A., Samaras, K., Thorisdottir, A., Kaufmann, G. R., Chisholm, D. J., & Cooper, D. A. (1999). Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet, 353, 2093-2099.
10. Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J., et al. (2003). Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42, 1206-1252.
11. Chun, T. W., Stuyver, L., Mizell, S. B., Ehler, L., Mican, J. A. M., Baseler, M., et al. (1997). Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America, 94, 13193-13197.
12. Clark, L. T., Ferdinand, K. C., Flack, J. M., Gavin, J. R., Hall, W. D., Kumanyika, S. K., et al. (2001). Coronary heart disease in African Americans. Heart Disease, 3, 97-108.
13. Clingerman, E. (2004). Physical activity, social support, and health-related quality of life among persons with HIV disease. Journal of Community Health Nursing, 21, 179-197.
14. Collins, R. L., Kanouse, D. E., Gifford, A. L., Senterfitt, J. W., Schuster, M. A., McCaffrey, D. F., et al. (2001). Changes in health-promoting behavior following diagnosis with HIV: prevalence and correlates in a national probability sample. Health Psychology, 20, 351-360.
15. Currier, J. S., Taylor, A., Boyd, P., Dezii, C. M., Kawabata, H., Burtcel, B., et al. (2003). Coronary heart disease in HIV-infected individuals. Journal of Acquired Immune Deficiency Syndromes, 33, 506-512.
16. d'Arminio, A., Sabin, C. A., Phillips, A. N., Reiss, P., Weber, R., Kirk, O., et al. for the D:A:D Study Group (2004). Cardio- and cerebrovascular events in HIV-infected persons. AIDS, 18, 1811-1817.
17. Ena, J., Benito, C., Llacer, P., Pasquau, F., & Amador, C. (2004). Abnormal body fat distribution and type of antiretroviral therapy as predictors of cardiovascular disease risk in HIV-infected patients. Medical Clinics, 122, 746-747.
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001). Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Adults (Adult Treatment Panel III). Journal of the American Medical Association, 285, 2486-2497.
19. Ferdinand, K. C., & Clark, L. T. (2004). The epidemic of diabetes mellitus and the metabolic syndrome in African Americans, Reviews in Cardiovascular Medicine, 5(Suppl. 3), S28-S33.
20. Ford, E. S., Giles, W. H., & Mokdad, A. H. (2004). Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care, 27, 2444-2449.
21. Friis-Moller, N., Sabin, C. A., Weber, R., d'Arminio, M. A., El-Sadr, W. M. Reiss, P., et al. for The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group (2003). Combination antiretroviral therapy and the risk of myocardial infarction. New England Journal of Medicine, 349, 993-2003
22. Gomez A. F., Romero S. P., Bernal A. A., Garcia-Egido M. A., Escobar J. J. B., & Lopez-Saez P. R. (2001, December). Dyslipidemia and hyperinsulinemia in HIV patients on HAART (Abstract No. 222). Paper presented at the 41st Interscience Conference on Antimocribial Agents and Chemotherapy, Chicago.
23. Gordon, N. F., Salmon, R. D., Franklin, B. A., Sperling, L. S., Hall, L., Leighton, R. F., et al. (2004). Effectiveness of therapeutic lifestyle changes in patients with hypertension, hyperlipidemia, and/or hyperglycemia. American Journal of Cardiology, 94, 1558-1561.
24. Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B. et al. for the Coordinating Committee of the National Cholesterol Education Program. (2004). Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines, Journal of the American College of Cardiology, 44, 720-732.
25. Grunfeld, C., & Tien, P. (2003). Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome. Clinical Infectious Disease, 37(Suppl. 2), S43-S46.
26. Hadigan, C., Jeste, S., Anderson, E. J., Tsay, R., Cyr, H., Grinspoon, S. (2001). Modifiable dietary habits and their relation to metabolic abnormalities in men and women with human immunodeficiency virus infection and fat redistribution. Clinical Infectious Disease, 33, 710-717.
27. Hatano, H., Miller, K. D., Yoder, C. P., Yansvski, J. A., Sebring, N. G., Jones, E. C., et al. (2000). Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. AIDS, 14, 1935-1942.
28. Heath, K. V., Hogg, R. S., Chan, K. J., Harris, M., Montessori, V., O'Shaughnessy, M. V., et al. (2001). Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS, 15, 231-239.
29. Hlatky, M. A., Boineau, R. F., Higginbotham, M. B., Lee, K. L., Mark, D. B., Califf, R. M., et al. (1989), A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). American Journal of Cardiology, 64, 651-654.
30. Kotler, D., Rosenbaum, K., Wang, J., & Pierson, R. (1999). Studies of body composition and fat distribution in HIV-infected and control subjects. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 20, 228-237.
31. Lowe, M. R., Chuck, S. K., & Penzak, S. R. (2001, December). Efficacy and safety of Pravastatin in protease inhibitor-related hyperlipidemia (PIH) (Abstract No. 228). Paper presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago.
32. Nixon, S., O'Brien, K., Glazier, R. H., & Wilkins, A. L. (2001). Aerobic exercise interventions for people with HIV/AIDS. Cochrane Database Systematic Review, 1, CD001796.
33. Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., et al., for The HIV Outpatient Study Investigators. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine, 338, 853-860.
34. Periard, D., Telenti, A., Sudre, P., Cheseaux, J. J., Halfon, P., Reymond, M. J., et al. (1999). Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation, 100, 700-705.
35. Pi-Sunyer X., Becker D. M., Bouchard C., Carleton R. A., Colditz G. A., Dietz W. H. et al. for the National Heart, Lung, and Blood Institute Obesity Education Initiative Task Force (1998). Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The evidence report. NIH publication 98-4083, Washington, DC: U.S. Department of Health and Human Services.
36. Rhew, D. C., Bernal, M., Aguilar, D., Iloeje, U., & Goetz, M. B. (2003). Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: A systematic review. Clinical Infectious Disease, 7, 959-972.
37. Saves, M., Raffi, F., Capeau, J., Rozenbaum, W., Ragnaud, J. M., & Perrone, C. (2002). Factors related to lipodystrophy and metabolic alterations in human immunodeficiency virus infection receiving highly active antiretroviral therapy, Clinical Infectious Disease, 34, 1396-1405.
38. Schwarcz, S. K., Hsu, L. C., Vittinghoff, E., & Katz, M. H. (2000). Impact of protease inhibitors and other antiretroviral treatments on acquired immunodeficiency syndrome survival in San Francisco, California, 1987-1996. American Journal of Epidemiology, 152, 178-185.
39. Taylor W., Hepworth J., Lees E., Cassells A., Gousse Y., Sweeney M. M., et al. (2004). Readiness to change physical activity and dietary practices and willingness to consult healthcare providers. Health Research Policy and Systems, 2, 2.
40. Tershakovec, A. M., Frank, I., & Rader, D. (2004). HIV-related lipodystrophy and related risk factors. Atherosclerosis, 174, 1-10.
41. Walker, S. N., Sechrist, K. R., & Pender, N. J. (1987). Health Promoting Lifestyle Profile: Development and psychometric characteristics. Nursing Research, 32, 76-81.
42. Walker S. N., Sechrist K. R., & Pender N. K. (1995). Health Promoting Lifestyle Profile, II. Omaha, NE: Author.
43. Walli, R., Herfort, O., Michl, G., Demant, T., Jager, H., Dieterle, C., et al. (1998). Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS, 12, F167-F173.
44. Willett, W. (1998). Anthropometric measures and body composition. In: Willett (Ed.), W. Nutritional Epidemiology (2nd ed.) (pp. 244-272). New York: Oxford University Press.
45. Yeni, P. G., Hammer, S. M., Carpenter, C. C., Cooper, D. A., Fischl, M. A., Gatell, J. M. et al. (2002). Antiretroviral treatment for adult HIV infection in 2002: Updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association, 288, 222-235.